View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2016	Nov. 07, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Entity Registrant Name	FLAMEL TECHNOLOGIES SA
Entity Central Index Key	0001012477
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Trading Symbol	FLML
Entity Common Stock, Shares Outstanding		41,241,254

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Product sales and services	$ 31,340	$ 47,313	$ 104,858	$ 128,441
License and research revenue	747	0	2,303	0
Total	32,087	47,313	107,161	128,441
Operating expenses:
Cost of products and services sold	2,844	2,087	10,657	8,473
Research and development expenses	8,143	7,221	21,135	20,447
Selling, general and administrative expenses	12,740	4,568	33,491	14,904
Intangible asset amortization	3,702	3,141	10,918	9,423
Changes in fair value of related party contingent consideration	20,848	44,782	52,989	82,036
Total	48,277	61,799	129,190	135,283
Operating loss	(16,190)	(14,486)	(22,029)	(6,842)
Investment income, net	490	197	1,080	1,171
Interest expense, net	(264)	0	(702)	0
Other expense - changes in fair value of related party payable	(1,828)	(6,644)	(6,135)	(9,629)
Foreign exchange gain (loss)	1,249	160	(12)	8,096
Loss before income taxes	(16,543)	(20,773)	(27,798)	(7,204)
Income tax provision	3,451	7,302	18,212	24,516
Net loss	$ (19,994)	$ (28,075)	$ (46,010)	$ (31,720)
Net loss per share - basic (in dollars per share)	$ (0.48)	$ (0.69)	$ (1.12)	$ (0.79)
Net loss per share - diluted (in dollars per share)	$ (0.48)	$ (0.69)	$ (1.12)	$ (0.79)
Weighted average number of shares outstanding - basic (in shares)	41,241	40,625	41,241	40,397
Weighted average number of shares outstanding - diluted (in shares)	41,241	40,625	41,241	40,397

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Other Comprehensive Income (Loss), Tax [Abstract]
Net loss	$ (19,994)	$ (28,075)	$ (46,010)	$ (31,720)
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	1,567	102	3,927	(11,285)
Net other comprehensive (loss) income, net of $152, ($9), ($49), ($9) tax, respectively	(2,405)	(365)	(958)	(365)
Total other comprehensive income (loss), net of tax	(838)	(263)	2,969	(11,650)
Total comprehensive loss	$ (20,832)	$ (28,338)	$ (43,041)	$ (43,370)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parentheticals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement of Comprehensive Income [Abstract]
Unrealized gain (loss) on marketable securities, tax	$ 152	$ (9)	$ (49)	$ (9)

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 18,780	$ 65,064
Marketable securities	130,887	79,738
Accounts receivable	15,395	7,487
Inventories	3,909	3,666
Research and development tax credit receivable	0	2,382
Prepaid expenses and other current assets	8,883	8,064
Total current assets	177,854	166,401
Property and equipment, net	3,186	2,616
Goodwill	19,134	18,491
Intangible assets, net	25,508	15,825
Research and development tax credit receivable	4,240	0
Income tax deferred charge	11,243	11,581
Other	6,820	167
Total assets	247,985	215,081
Current liabilities:
Current portion of long-term debt	286	434
Current portion of long-term related party payable	33,359	25,204
Accounts payable	8,966	5,048
Deferred revenue	3,115	5,121
Accrued expenses	13,032	9,308
Other	427	133
Total current liabilities	59,185	45,248
Long-term debt, less current portion	734	684
Long-term related party payable, less current portion	146,926	97,489
Other	4,307	2,526
Total liabilities	211,152	145,947
Shareholders' equity:
Ordinary shares, nominal value of 0.122 euro per share; 53,178 shares authorized; 41,241 issued and outstanding at September 30, 2016 and December 31, 2015	6,331	6,331
Additional paid-in capital	374,724	363,984
Accumulated deficit	(324,534)	(278,524)
Accumulated other comprehensive loss	(19,688)	(22,657)
Total shareholders' equity	36,833	69,134
Total liabilities and shareholders' equity	$ 247,985	$ 215,081

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - € / shares shares in Thousands	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value (in euro per share)	€ 0.122	€ 0.122
Common stock, shares authorized (in shares)	53,178	53,178
Common stock, shares issued (in shares)	41,241	41,241
Common stock, shares outstanding (in shares)	41,241	41,241

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (46,010)	$ (31,720)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	11,555	9,800
Loss on disposal of property and equipment	110	0
Loss on sale of marketable securities	666	443
Foreign exchange loss (gain)	12	(7,475)
Grants recognized in research and development expenses	(70)	(1,086)
Remeasurement of related party acquisition-related contingent consideration	52,989	82,036
Remeasurement of related party financing-related contingent consideration	6,135	9,629
Change in deferred tax and income tax deferred charge	(5,680)	(745)
Stock-based compensation expense	10,541	5,574
Increase (decrease) in cash from:
Accounts receivable	(7,594)	(1,363)
Inventories	2,080	1,757
Prepaid expenses and other current assets	671	(4,005)
Research and development tax credit receivable	(1,794)	2,469
Accounts payable & other current liabilities	1,291	2,387
Deferred revenue	(2,198)	(1,318)
Accrued expenses	2,700	(1,048)
Accrued income taxes	0	(7,584)
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value	(14,486)	0
Royalty payments for related party payable in excess of original fair value	(1,790)	0
Other long-term assets and liabilities	2,032	144
Net cash provided by operating activities	11,160	57,895
Cash flows from investing activities:
Purchases of property and equipment	(1,000)	(1,077)
Acquisitions of businesses	628	0
Proceeds from sales of marketable securities	46,483	37,007
Purchase of marketable securities	(96,199)	(59,058)
Net cash used in investing activities	(50,088)	(23,128)
Cash flows from financing activities:
Earn-out payments for related party contingent consideration	(6,834)	(15,497)
Royalty payments for related party payable	(1,117)	(2,158)
Repayment of debt	0	(4,904)
Reimbursement of conditional grants	(61)	(681)
Cash proceeds from issuance of ordinary shares and warrants	0	6,990
Net cash used in financing activities	(8,012)	(16,250)
Effect of exchange rate changes on cash and cash equivalents	656	(2,236)
Net increase (decrease) in cash and cash equivalents	(46,284)	16,281
Cash and cash equivalents at January 1	65,064	39,760
Cash and cash equivalents at September 30	$ 18,780	$ 56,041

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Nature of Operations. Flamel Technologies S.A. (“Flamel,” the “Company,” “we” or “us”) is organized as a Société Anonyme, a form of corporation under the laws of The Republic of France. The Company was founded in 1990. Flamel is a specialty pharmaceutical company utilizing core competencies in drug delivery and formulation development to create safer and more efficacious pharmaceutical products to address unmet medical needs and/or reduce overall healthcare costs. The Company has a business model consisting of:

•

an Unapproved Marketed Drugs (“UMDs”) business with three approved products in the United States: Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection) and Akovaz® (ephedrine sulphate injection). On May 2, 2016, the company announced that the U.S. Food and Drug Administration (FDA) had approved the Company’s New Drug Application (NDA) for Akovaz™ (ephedrine sulfate), a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings. The NDA, which is the first to receive approval from the FDA for ephedrine sulfate, was approved on April 29, 2016. We began marketing Akovaz in a strength of 50mg/mL in the third quarter of 2016. We are also currently studying a fourth unapproved drug for possible submission for review by the FDA in early 2017. The UMD business was obtained through the acquisition of Éclat Pharmaceuticals, LLC ("Éclat"), on March 13, 2012;


•	a branded pediatric specialty pharmaceutical business with three FDA approved products and one FDA approved medical device, acquired through the acquisition of FSC Holdings, LLC (“FSC”) on February 5, 2016; and

•

a technology business, focusing on the development of products utilizing Flamel’s proprietary drug delivery platforms. The products that are based on Flamel’s proprietary drug delivery platforms target high-value solid and liquid oral and alternative dosage forms using 505(b)(2) and Biosimilar pathways where the Company is able to develop strong intellectual property positions and deliver meaningful patient benefits.

Flamel is headquartered in Lyon, France and has operations in St. Louis, Missouri, United States, and Dublin, Ireland.

Proposed Reincorporation as an Irish Public Limited Company (plc). At our shareholders meeting on August 10, 2016, our shareholders approved resolutions to change our jurisdiction of incorporation from France to Ireland. Based on such approval, we intend to give effect to this reincorporation on December 31, 2016 by merging with and into our wholly owned Irish corporate subsidiary, Avadel Pharmaceuticals Limited (the “Merger”). Prior to completing the Merger, Avadel Pharmaceuticals Limited will re-register as an Irish public limited company, or plc, and at the time of the Merger and thereafter our shareholders (and holders of our American Depositary Shares (ADSs)) will own shares (or ADSs, as applicable) in a company known as Avadel Pharmaceuticals plc. Our definitive proxy statement filed with the Securities and Exchange Commission on July 5, 2016 contains additional information about the proposed reincorporation.

Basis of Presentation. The Condensed Consolidated Balance Sheet as of December 31, 2015, which is primarily derived from the prior year 2015 audited consolidated financial statements, and the interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2015 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2016.

The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.

Foreign Currency Translation. The reporting currency of the Company and its wholly-owned subsidiaries is the U.S. dollar. Each of the Company's non-U.S. subsidiaries and the parent entity uses local currency as their functional currency. Subsidiaries and entities that do not use the U.S. dollar as their functional currency translate 1) profit and loss accounts at the weighted average exchange rates during the reporting period, 2) assets and liabilities at period end exchange rates and 3) shareholders' equity accounts at historical rates. Resulting translation gains and losses are included as a separate component of shareholders' equity in Accumulated Other Comprehensive Loss. Assets and liabilities, excluding available-for-sale marketable securities, denominated in a currency other than the subsidiary's functional currency are translated to the subsidiary's functional currency at period end exchange rates with resulting gains and losses recognized in the condensed consolidated statements of loss. Available-for-sale marketable securities denominated in a currency other than the subsidiary's functional currency are translated to the subsidiary's functional currency at period end exchange rates with resulting gains and losses recognized in the condensed consolidated statements of other comprehensive loss.

Reclassifications and Immaterial Corrections of Prior Period Amounts. The accompanying condensed consolidated financial statements for prior periods contain certain reclassifications to conform to the presentation used in 2016. Additionally, the Company has identified certain immaterial errors related to prior reporting periods. The Company has assessed the impact of the errors on its prior period financial statements included in our December 31, 2015 Annual Report on Form 10-K and concluded that the errors were not material to those financial statements. Although the effect of the errors was not material to any previously issued financial statements, the cumulative effect of correcting the errors would have been material for the period ended September 30, 2016. Consequently, the Company has presented the effects of these errors and reclassifications on its prior period financial statements in the tables below. In future filings the financial statements for comparative periods affected by these errors and reclassifications will be revised.

The impact of the above errors and reclassifications on previously presented line items for each comparative period presented is as follows:



	Three Months Ended September 30, 2015
				Correction of Immaterial Errors
Consolidated Statement of Loss:	As filed			(a)			(b)			(d)			(i)		As revised

Product sales and services	$	47,320		$	—		$	—		$	(1,200	)	$	1,193	$	47,313
Total revenue	47,320			—			—			(1,200		)	1,193		47,313
Operating income (loss)	(14,479		)	—			—			(1,200		)	1,193		(14,486		)
Income (loss) before income taxes	(20,766		)	—			—			(1,200		)	1,193		(20,773		)
Income tax provision	8,919			(863		)	(751		)	(420		)	417		7,302
Net loss	(29,685		)	863			751			(780		)	776		(28,075		)
Net loss per share - basic	$	(0.73	)	$	0.02		$	0.02		$	(0.02	)	$	0.02	$	(0.69	)
Net loss per share - diluted	$	(0.73	)	$	0.02		$	0.02		$	(0.02	)	$	0.02	$	(0.69	)



	Nine Months Ended September 30, 2015
				Correction of Immaterial Errors
Consolidated Statement of Loss:	As filed			(a)			(b)			(c)			(d)			As revised

Product sales and services	$	129,841		$	—		$	—		$	(200	)	$	(1,200	)	$	128,441
Total revenue	129,841			—			—			(200		)	(1,200		)	128,441
Operating income (loss)	(5,442		)	—			—			(200		)	(1,200		)	(6,842		)
Income (loss) before income taxes	(5,804		)	—			—			(200		)	(1,200		)	(7,204		)
Income tax provision	29,634			(2,021		)	(2,607		)	(70		)	(420		)	24,516
Net loss	(35,438		)	2,021			2,607			(130		)	(780		)	(31,720		)
Net loss per share - basic	$	(0.88	)	$	0.05		$	0.06		$	—		$	(0.02	)	$	(0.79	)
Net loss per share - diluted	$	(0.88	)	$	0.05		$	0.06		$	—		$	(0.02	)	$	(0.79	)



	December 31, 2015
				Correction of Immaterial Errors									Reclassifications
Consolidated Balance Sheet:	As filed			(a)			(e)			(f)			(g)			(h)		As revised

Accounts receivable	$	6,978		$	—		$	—		$	—		$	509		$	—	$	7,487
Inventories	4,155			—			(489		)	—			—			—		3,666
Prepaid expenses and other current assets	7,989			—			—			—			—			75		8,064
Total current assets	166,306			—			(489		)	—			509			75		166,401
Other	158			—			—			—			—			9		167
Total assets	214,977			—			(489		)	—			509			84		215,081
Current portion of long-term related party payable	28,614			—			—			(3,410		)	—			—		25,204
Accounts payable	10,565			—			—			—			(5,517		)	—		5,048
Accrued expenses	3,598			—			—			—			5,710			—		9,308
Income taxes	323			(227		)	(171		)	—			—			75		—
Total current liabilities	48,788			(227		)	(171		)	(3,410		)	193			75		45,248
Long-term related party payable, less current portion	94,079			—			—			3,410			—			—		97,489
Deferred taxes	1,351			(1,360		)	—			—			—			9		—
Other	2,210			—			—			—			316			—		2,526
Total liabilities	147,112			(1,587		)	(171		)	—			509			84		145,947
Accumulated deficit	(279,793		)	1,587			(318		)	—			—			—		(278,524		)
Total shareholders' equity	67,865			1,587			(318		)	—			—			—		69,134
Total liabilities and shareholders' equity	214,977			—			(489		)	—			509			84		215,081


(a)	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).

(b)

Reflects the correction of $2,607 of income tax benefits from stock-based compensation and certain other items which were originally recorded in the fourth quarter of 2015 but should have been recorded in prior periods ($360 in 2012, $333 in 2013, $(693) in 2014, and $830, $1,026 and $751 in the first, second and third quarters of 2015, respectively). As these items were originally corrected in the fourth quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.

(c)

Reflects the correction of a $200 overstatement of revenue in the first quarter of 2015 resulting from errors in certain estimates of ending inventory amounts at our wholesalers which were originally corrected in the first quarter of 2015 but should have been recorded in the fourth quarter of 2014. As this item was originally corrected in the first quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.


(d)	Reflects the correction of a $1,200 understatement in the third quarter of 2015 of the gross to net revenue reserves with respect to the Company’s customer rebate calculations. As this item was originally corrected in the fourth quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.


(e)	Reflects the correction of a $489 error in the Company’s inventory obsolescence reserve accrual and expense which was originally recorded in the first quarter of 2016 but should have been recorded in the fourth quarter of 2015.


(f)	Reflects the correction of a balance sheet classification error which overstated the current portion of the long-term related party payable by $3,410.


(g)	Reflects revisions to the presentation of certain gross to net revenue reserves which were previously included in accounts payable and are now included in accrued expenses.


(h)	Reflects balance sheet reclassifications required to properly net the accrued income tax and deferred income tax amounts within the balance sheet as a result of the adjustments made in items (a) through (g) above.

(i)

Reflects the correction of a $1,193 understatement in the second quarter of 2015 of the gross to net revenue reserves with respect to estimates for product returns as a result of improper reconciliation to revenue data communicated by service providers. As this item was originally corrected in the third quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.

In addition to the specific amounts identified within the tables above, the Company also changed the names of the previously-reported “Interest expense – changes in fair value of related party financing related contingent consideration” line on the condensed consolidated statement of income (loss) to “Other expense – changes in fair value of related party payable”, and the previously-reported “Long-term related party contingent consideration payable” line on the condensed consolidated balance sheet to “Long-term related party payable” to better reflect the underlying nature of certain royalty agreements in prior periods.

While the balance sheet revisions and reclassifications noted in the tables above impact their corresponding captions within the cash flows provided by (used in) operating activities section of the Company’s consolidated statements of cash flows in each period of 2015, there was no impact to the total net cash provided by (used in) operating activities in any of these periods.

Revenue. Revenue includes sales of pharmaceutical products, amortization of licensing fees, and if any, milestone payments for R&D achievements.

Product Sales and Services

Revenue is generally realized or realizable and earned when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. The Company records revenue from product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery to the customer and when the selling price is determinable. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of deductions in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

For generic products and branded products sold in mature markets where the ultimate net selling price to customer is estimable, the Company recognizes revenues upon shipment to the wholesaler. For new product launches the Company recognizes revenue once sufficient data is available to determine product acceptance in the marketplace such that product returns may be estimated based on historical data and there is evidence of reorders and consideration is made of wholesaler inventory levels. As part of the third quarter 2016 launch of Akovaz, the Company determined that sufficient data was available to determine the ultimate net selling price to the customer and therefore recognized revenue upon shipment to its wholesaler customers.

Prior to the second quarter 2016, the Company did not have sufficient historical data to estimate certain revenue deductions. As such, it could not accurately estimate the ultimate net selling price of its Éclat portfolio of products and as a result delayed revenue recognition until the wholesaler sold the product through to its customers.

During the second quarter of 2016, the Company determined that it has sufficient evidence, history, data and internal controls to estimate the ultimate selling price of its products upon shipment from its warehouse to its customers, the wholesalers. Accordingly, it discontinued the sell through revenue approach and now recognizes revenue once the product is shipped from its warehouse. As a result of this change in accounting estimate, the Company recognized $5,981 in additional revenue, or $0.05 in additional diluted net earnings (loss) per share, for the nine months ended September 30, 2016 that previously would have been deferred until sold by the wholesalers to the hospitals.

License and Research Revenue

The Company’s license and research revenues consist of fees and milestone payments. Non-refundable fees where we have continuing performance obligations are deferred and are recognized ratably over our projected performance period. We recognize milestone payments, which are typically related to regulatory, commercial or other achievements by us or our licensees and distributors, as revenues when the milestone is accomplished and collection is reasonably assured. As of September 30, 2016, the Company has not recognized any revenue from milestone payments.

Newly Issued Accounting Pronouncements	9 Months Ended
Newly Issued Accounting Pronouncements	Sep. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Newly Issued Accounting Pronouncements	Newly Issued Accounting Pronouncements In August 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU”) 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows under Topic 230. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” which supersedes the most current revenue recognition requirements. This ASU requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. Through May 2016, the FASB issued ASU 2016-08 “Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU 2016-10 “Identifying Performance Obligations and Licensing,” and ASU 2016-12, “Narrow-Scope Improvements and Practical Expedients,” which provide supplemental adoption guidance and clarification to ASU 2014-09, respectively. These ASUs will be effective for annual and interim periods beginning after December 15, 2017 with early adoption for annual and interim periods beginning after December 15, 2016 permitted and should be applied retrospectively to each prior reporting period presented or as a cumulative effect adjustment as of the date of adoption. The Company is currently evaluating this pronouncement to determine the impact of its adoption on its condensed consolidated financial statements. In March 2016, the FASB issued ASU 2016-09 “Improvements to Employee Share-Based Payment Accounting” which amends Accounting Standards Codification (“ASC”) Topic 718 “Compensation – Stock Compensation”. This update simplifies several aspects of accounting for share-based payment awards to employees, including the accounting for income taxes, classification of awards as either equity or liabilities and classification in the statement of cash flows. The standard is effective for annual reporting periods beginning after December 15, 2016. The Company does not believe this standard will materially impact its condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02 “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. This update will be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the effect of this update on its condensed consolidated financial statements. In September 2015, the FASB issued ASU 2015-16 “Business Combinations” which requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This ASU is effective for interim and annual reporting periods beginning after December 15, 2016, with the option to early adopt for financial statements that have not been issued. The Company early adopted the provisions of ASU 2015-16 for the year ended December 31, 2015 on a prospective basis. In July 2015, the FASB issued ASU 2015-11 “Simplifying the Measurement of Inventory" which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The effective date for the standard is for fiscal years beginning after December 15, 2016. The new standard is to be applied prospectively and early adoption is permitted. The Company does not expect ASU 2015-11 to have a material impact on its condensed consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

Marketable Securities

9 Months Ended

Sep. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Marketable Securities

The Company has investments in available-for-sale marketable equity securities which are recorded at fair market value and measured using quoted prices in their respective active market, thus representing a level 1 fair value measurement as defined in ASC 820. Unrealized gains and losses are recorded as other comprehensive income (loss) in shareholders’ equity, net of income tax effects.

The value at cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale marketable securities are summarized below as of:



	September 30, 2016			December 31, 2015
Marketable Securities:	September 30, 2016			December 31, 2015

Value at cost	$	131,147		$	81,395
Gross unrealized holding gains	805			15
Gross unrealized holding losses	(1,065		)	(1,672		)
Fair value	$	130,887		$	79,738

Inventories

9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

Inventories

The principal categories of inventories at September 30, 2016 and December 31, 2015 are as follows:



	September 30, 2016		December 31, 2015
Inventory:	September 30, 2016		December 31, 2015

Finished goods	$	2,410	$	2,545
Raw materials	1,499		1,121
Total	$	3,909	$	3,666

Acquisitions

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

Acquisitions

On February 5, 2016, the Company completed its acquisition of FSC, previously a Charlotte, North Carolina-based specialty pharmaceutical company dedicated to providing innovative solutions to unmet medical needs for pediatric patients, from Deerfield CSF, LLC, a Deerfield Management company (“Deerfield”), a related party.

This acquisition has been accounted for using the acquisition method of accounting and, accordingly, its results are included in the Company's condensed consolidated financial statements from the date of acquisition. Total consideration to acquire FSC is estimated to be $22,228, and was funded with a combination of the following, partially offset by $467 as a result of a net working capital settlement from the seller:


•	$15,000 long-term liability to Deerfield. Under the terms of the acquisition agreement, the Company will pay $1,050 annually for five years with a final payment in January 2021 of $15,000.


•	$7,695 contingent consideration to Deerfield. Under the terms of the acquisition agreement, the Company shall pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.

The present value of these items is reported in related party payable within the Company’s condensed consolidated balance sheet, and is further disclosed at Note 7 – Long-Term Related Party Payable.

The Company determined a preliminary purchase price allocation as noted in the following table. This preliminary allocation could change as the Company completes its final accounting for the acquisition, which may include adjustments to the items noted below. The preliminary fair values assigned to the acquired assets and liabilities have been recognized as follows:



	2016
Assigned Fair Value:	Preliminary

Accounts receivable	$	825
Inventories	2,315
Prepaid expenses and other current assets	1,712
Goodwill	643
Intangible assets:
Acquired product marketing rights	16,200
Acquired developed technology	4,400
Other assets	277
Accounts payable and other current liabilities	(4,144		)
Total	$	22,228

Goodwill resulting from the acquisition is largely attributable to the existing workforce of FSC, and is not expected to be deductible for tax purposes. Transaction expenses were not material for the three and nine month periods ended September 30, 2016. The useful lives on FSC acquired intangible assets range from seven to ten years.

After its acquisition on February 5, 2016, FSC contributed $389 and $3,026 to the Company's net sales for the three and nine month periods ended September 30, 2016, respectively. FSC incurred a loss of $4,508 and $8,997 for the three and nine month periods ended September 30, 2016, respectively.

Had the FSC acquisition been completed as of the beginning of 2015, the Company's unaudited pro forma net sales and net loss for the nine months ended September 30, 2016 and 2015 would have been as follows:



	Nine Months Ended
Pro Forma Net Revenue and Losses	September 30, 2016			September 30, 2015

Net revenues	$	107,636		$	132,318
Net loss	(47,024		)	(40,724		)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

The Company's amortizable and unamortizable intangible assets at September 30, 2016 and December 31, 2015 are as follows:



	September 30, 2016							December 31, 2015
	Gross Value		Accumulated Amortization			Net Carrying Amount		Gross Value		Accumulated Amortization			Net Carrying Amount

Amortizable intangible assets:
Acquired developed technology - Bloxiverz	$	35,248	$	(32,311	)	$	2,937	$	35,248	$	(23,498	)	$	11,750
Acquired developed technology - Vazculep	12,061		(8,597		)	3,464		12,061		(7,986		)	4,075
Acquired developed technology - Flexichamber	4,400		(293		)	4,107		—		—			—
Acquired product marketing rights	16,200		(1,200		)	15,000		—		—			—
Total amortizable intangible assets	$	67,909	$	(42,401	)	$	25,508	$	47,309	$	(31,484	)	$	15,825

Unamortizable intangible assets:
Goodwill	$	19,134	$	—		$	19,134	$	18,491	$	—		$	18,491
Total unamortizable intangible assets	$	19,134	$	—		$	19,134	$	18,491	$	—		$	18,491

The Company recorded amortization expense related to amortizable intangible assets of $3,702 and $3,141 for the three months ended September 30, 2016 and 2015, respectively. The Company recorded amortization expense related to amortizable intangible assets of $10,918 and $9,423 for the nine months ended September 30, 2016 and 2015, respectively. Accumulated amortization in the above tables includes an impairment charge of $7,171 which was recognized during the year ended December 31, 2012 relative to the “Acquired developed technology – Vazculep” intangible asset.

Amortizable intangible assets are amortized over their estimated useful lives, which range from three to ten years. Estimated amortization of intangible assets for the next five years is as follows:



Years ending December 31,	Estimated Amortization Expense

2016	$	14,616
2017	3,056
2018	3,056
2019	3,056
2020	3,056
Total	$	26,840

The change in net goodwill during the nine months ended September 30, 2016 is as follows:



Goodwill:

Balance, December 31, 2015	$	18,491
Impact of FSC acquisition	643
Balance, September 30, 2016	$	19,134

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Long-Term Related Party Payable

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Long-Term Related Party Payable

Long-term related party payable and related activity are reported at fair value and consist of the following at September 30, 2016 and June 30, 2016:



				Activity during the Three Months Ended September 30, 2016
									Changes in Fair Value of Related Party Payable
	Balance, June 30, 2016			Additions		Payments to Related Parties			Operating Expense			Other Expense		Balance, September 30, 2016

Acquisition-related contingent consideration:
Warrants - Éclat Pharmaceuticals (a)	$	15,462		$	—	$	—		$	2,058		$	—	$	17,520
Earn-out payments - Éclat Pharmaceuticals (b)	114,614			—		(6,719		)	19,720			—		127,615
Royalty agreement - FSC (c)	6,505			—		(261		)	(930		)	—		5,314
Financing-related:
Royalty agreement - Deerfield (d)	9,440			—		(630		)	—			1,237		10,047
Royalty agreement - Broadfin (e)	4,500			—		(301		)	—			590		4,789
Long-term liability - FSC (f)	15,000			—		—			—			—		15,000
Total related party payable	165,521			$	—	$	(7,911	)	$	20,848		$	1,827	180,285
Less: Current portion	(29,500		)											(33,359		)
Total long-term related party payable	$	136,021												$	146,926

Long-term related party payable and related activity are reported at fair value and consist of the following at September 30, 2016 and December 31, 2015:



				Activity during the Nine Months Ended September 30, 2016
									Changes in Fair Value of Related Party Payable
	Balance, December 31, 2015			Additions		Payments to Related Parties			Operating Expense			Other Expense		Balance, September 30, 2016
Acquisition-related contingent consideration:
Warrants - Éclat Pharmaceuticals (a)	$	20,617		$	—	$	—		$	(3,097	)	$	—	$	17,520
Earn-out payments - Éclat Pharmaceuticals (b)	90,468			—		(20,934		)	58,081			—		127,615
Royalty agreement - FSC (c)	—			7,695		(386		)	(1,995		)	—		5,314
Financing-related:
Royalty agreement - Deerfield (d)	7,862			—		(1,968		)	—			4,153		10,047
Royalty agreement - Broadfin (e)	3,746			—		(939		)	—			1,982		4,789
Long-term liability - FSC (f)	—			15,000		—			—			—		15,000
Total related party payable	122,693			$	22,695	$	(24,227	)	$	52,989		$	6,135	180,285
Less: Current portion	(25,204		)											(33,359		)
Total long-term related party payable	$	97,489												$	146,926

(a)

As part of the consideration for the Company’s acquisition of Éclat on March 13, 2012, the Company issued two warrants to a related party with a six-year term which allow for the purchase of a combined total of 3,300 ordinary shares of Flamel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share.

The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of September 30:



Assumptions for the Warrant Valuation	September 30, 2016			September 30, 2015

Stock price	$	12.40		$	16.31
Weighted average exercise price per share	8.63			8.63
Expected term (years)	1.5			2.5
Expected volatility	58.40		%	64.87		%
Risk-free interest rate	0.68		%	0.78		%
Expected dividend yield	—			—

These Black-Scholes fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. The fair value of the warrant consideration is most sensitive to movement in the Company’s share price and expected volatility at the balance sheet date.

Expected term: The expected term represents the remaining life of the warrants at the balance sheet date.

Expected volatility: The expected volatility is calculated based on an average of the historical volatility of the Company's stock price for a period approximating the expected term.

Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and a maturity that approximates the expected term.

Expected dividend yield: The Company has not distributed any dividends since its inception and has no plan to distribute dividends in the foreseeable future.

At the closing date of the 2012 Éclat acquisition and at September 30, 2016, it was uncertain as to whether the Company would ultimately fulfill its obligation under these warrants using Company shares or cash. Accordingly, pursuant to the guidance of ASC 480, the Company determined that these warrants should be classified as a long-term liability. This classification as a long-term liability was further supported by the Company’s determination, pursuant to the guidance of ASC 815-40-15-7(i), that these warrants could also not be considered as being indexed to the Company’s own stock, on the basis that the exercise price for the warrants is determined in U.S. dollars, although the functional currency of the Company at the closing date of the Éclat acquisition was the Euro.

(b)

In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by Mr. Michael Anderson, the Company’s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.


(c)	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part included a commitment to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.


(d)	As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024.


(e)	As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.


(f)	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part consists of payments totaling $1,050 annually for five years with a final payment in January 2021 of $15,000.

At September 30, 2016, the fair value of each related party payable listed in (b) through (e) above was estimated using a discounted cash flow model based on probability-adjusted annual net revenues or gross profit, as appropriate, of each of the specified Éclat and FSC products using an appropriate risk-adjusted discount rate ranging from 15% to 32%. These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related contingent consideration payable, resulting primarily from management’s revision of key assumptions, will be recorded in the ‘Changes in fair value of related party contingent consideration’ line within the Company’s condensed consolidated statements of loss.

The Company has chosen to make a fair value election pursuant to ASC 825, “Financial Instruments” for its royalty agreements detailed in items (d) and (e) above. These financing-related liabilities are recorded at fair market value on the condensed consolidated balance sheets and the periodic change in fair market value is recorded as a component of “Other expense – change in fair value of related party payable” on the condensed consolidated statements of loss.

Income Taxes

9 Months Ended

Sep. 30, 2016

Income Tax Disclosure [Abstract]

Income Taxes

The components of income (loss) before income taxes are as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015

United States	$	(6,814	)	$	(9,581	)	$	4,948		$	11,192
France	(6,244		)	(5,568		)	(15,333		)	3,545
Ireland	(3,485		)	(5,624		)	(17,413		)	(21,941		)
Total loss before income taxes	$	(16,543	)	$	(20,773	)	$	(27,798	)	$	(7,204	)

The items accounting for the difference between the income tax provision computed at the French statutory rate and the Company's effective tax rate are as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015

Statutory tax rate	33.3		%	33.3		%	33.3		%	33.3		%
International tax rates differential	(3.6		)%	(4.8		)%	(13.3		)%	(66.0		)%
Valuation allowance on net operating losses	(2.0		)%	10.2		%	(15.3		)%	24.8		%
Nondeductible contingent consideration	(38.9		)%	(67.9		)%	(62.0		)%	(367.0		)%
Nondeductible stock-based compensation	(4.8		)%	1.7		%	(4.4		)%	54.6		%
Deferred charge from IP transfer	(1.5		)%	(2.7		)%	(2.7		)%	(8.8		)%
State and local income taxes	(1.7		)%	(1.3		)%	(2.7		)%	(7.1		)%
Other	(1.7		)%	(3.7		)%	1.6		%	(4.1		)%
Effective income tax rate	(20.9		)%	(35.2		)%	(65.5		)%	(340.3		)%

Income tax benefit - at statutory tax rate	$	(5,509	)	$	(6,917	)	$	(9,257	)	$	(2,399	)
International tax rates differential	591			1,006			3,706			4,754
Valuation allowance on net operating losses	339			(2,116		)	4,252			(1,784		)
Nondeductible contingent consideration	6,436			14,109			17,236			26,438
Nondeductible stock-based compensation	788			(357		)	1,222			(3,936		)
Deferred charge from IP transfer	246			568			739			637
State and local income taxes	280			260			757			515
Other	280			749			(443		)	291
Income tax provision - at effective income tax rate	$	3,451		$	7,302		$	18,212		$	24,516

The income tax provision for the three months ended September 30, 2016 and 2015 was $3,451 and $7,302, respectively. The decrease in the income tax provision for the three months ended September 30, 2016 is primarily the result of a decrease in the amount of nondeductible contingent consideration when compared to the same period in 2015. The decrease in the income tax provision for the three months ended September 30, 2016 would have been larger, but release of $3,360 in valuation allowances recorded in the same period in 2015 did not repeat in 2016.

The income tax provision for the nine months ended September 30, 2016 and 2015 was $18,212 and $24,516. The decrease in the income tax provision for the nine months ended September 30, 2016 is primarily the result of a decrease in the amount of nondeductible contingent consideration and decreases in the amount of pre-tax income recorded in the United States and France, when compared to the same period in 2015. These benefits were partially offset by an increase of $3,343 in valuation allowances recorded against net operating losses during the nine months ended September 30, 2016.

Other Assets and Liabilities

9 Months Ended

Sep. 30, 2016

Other Liabilities Disclosure [Abstract]

Other Assets and Liabilities

Various other assets and liabilities are summarized as follows:



	September 30, 2016		December 31, 2015
Prepaid Expenses and Other Current Assets:	September 30, 2016		December 31, 2015

Valued-added tax recoverable	$	305	$	1,099
Prepaid expenses	4,456		2,921
Advance to suppliers and other current assets	1,603		518
Income tax receivable	2,519		3,526
Total	$	8,883	$	8,064



	September 30, 2016		December 31, 2015
Other Non-Current Assets:	September 30, 2016		December 31, 2015

Deferred tax assets	$	6,715	$	—
Other	105		167
Total	$	6,820	$	167



	September 30, 2016		December 31, 2015
Accrued Expenses:	September 30, 2016		December 31, 2015

Compensation	$	2,797	$	1,888
Social charges	1,556		1,710
Customer allowances	8,094		5,710
Other	585		—
Total	$	13,032	$	9,308



	September 30, 2016		December 31, 2015
Other Current Liabilities:	September 30, 2016		December 31, 2015

Valued-added tax payable	$	91	$	—
Other	336		133
Total	$	427	$	133



	September 30, 2016		December 31, 2015
Other Non-Current Liabilities:	September 30, 2016		December 31, 2015

Provision for retirement indemnity	$	2,324	$	2,170
Customer allowances	1,556		—
Other	427		356
Total	$	4,307	$	2,526

Net Loss Per Share

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Net Loss Per Share

Basic net loss per share is calculated using the weighted average number of shares outstanding during each period. The diluted net loss per share calculation includes the impact of dilutive equity compensation awards and contingent consideration warrants.

A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
Loss Per Share	2016			2015			2016			2015

Net loss	$	(19,994	)	$	(28,075	)	$	(46,010	)	$	(31,720	)

Weighted average shares:
Basic shares	41,241			40,625			41,241			40,397
Effect of dilutive securities—options and warrants outstanding	—			—			—			—
Diluted shares	41,241			40,625			41,241			40,397

Net loss per share - basic	$	(0.48	)	$	(0.69	)	$	(1.12	)	$	(0.79	)
Net loss per share - diluted	$	(0.48	)	$	(0.69	)	$	(1.12	)	$	(0.79	)

Potential common shares of 6,860 and 6,088 were excluded from the calculation of weighted average shares for the three and nine months ended September 30, 2016 and 2015, respectively, because their effect was considered to be anti-dilutive.

Comprehensive Income (Loss)

9 Months Ended

Sep. 30, 2016

Stockholders' Equity Note [Abstract]

Comprehensive Income (Loss)

The following table shows the components of accumulated other comprehensive loss for the three and nine months ended September 30, 2016 and 2015, net of tax effects:



	Three Months Ended September 30,						Nine Months Ended September 30,
Accumulated Other Comprehensive Loss	2016			2015			2016			2015

Foreign currency translation adjustment:
Beginning balance	$	(19,952	)	$	(18,612	)	$	(22,312	)	$	(7,225	)
Net other comprehensive (loss) income	1,567			102			3,927			(11,285		)
Balance at September 30	$	(18,385	)	$	(18,510	)	$	(18,385	)	$	(18,510	)

Unrealized gain (loss) on marketable securities, net
Beginning balance	$	1,102		$	(198	)	$	(345	)	$	(198	)
Net other comprehensive (loss) income, net of $152, ($9), ($49), ($9) tax, respectively	(2,405		)	(365		)	(958		)	(365		)
Balance at September 30	$	(1,303	)	$	(563	)	$	(1,303	)	$	(563	)
Accumulated other comprehensive loss at September 30	$	(19,688	)	$	(19,073	)	$	(19,688	)	$	(19,073	)

The effect on the Company’s condensed consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Shareholders' Equity

9 Months Ended

Sep. 30, 2016

Stockholders' Equity Note [Abstract]

Shareholders' Equity

Shareholders’ Equity

The following table presents a reconciliation of the Company’s beginning and ending balances in shareholders’ equity for the nine months ended September 30, 2016:



	Nine Months Ended September 30, 2016
Shareholders' Equity	Nine Months Ended September 30, 2016

Shareholders' equity - January 1	$	69,134
Net loss	(46,010		)
Other comprehensive income	2,969
Subscription of warrants	199
Stock-based compensation expense	10,541
Shareholders' equity - September 30	$	36,833

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Company Operations by Product

9 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

Company Operations by Product

The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company's Chief Operating Decision Maker is the CEO. The CEO and the Board review profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the majority of our products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

The following table presents a summary of total revenues by these products:



	Three Months Ended September 30,				Nine Months Ended September 30,
Revenues	2016		2015		2016		2015

Bloxiverz	$	15,591	$	41,243	$	65,958	$	114,074
Vazculep	9,340		5,605		29,167		12,757
Akovaz	5,568		—		5,568		—
Other	841		465		4,165		1,610
Total product sales and services	31,340		47,313		104,858		128,441
License and research revenue	747		—		2,303		—
Total revenues	$	32,087	$	47,313	$	107,161	$	128,441

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At September 30, 2016 and December 31, 2015, there were no contingent liabilities with respect to any threat of litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company’s condensed consolidated financial position, results of operations, cash flows or liquidity. Material Commitments Other than commitments to Recipharm and for operating leases as disclosed in Note 12 - Contingent Liabilities and Commitments to the Company's consolidated financial statements included in Part II, Item 8 of the Company’s 2015 Annual Report, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt and post-retirement benefit plan obligations which are disclosed in Note 7 - Long-Term Debt and Note 10 – Post-Retirement Benefit Plans, respectively, to the Company's consolidated financial statements included in Part II, Item 8 of the Company’s 2015 Annual Report and long-term contingent consideration payable as disclosed in Note 7 – Long-Term Related Party Payable, to the Company's condensed consolidated financial statements included in Part I, Item 1 of this report.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Nature of Operations

•


•	a branded pediatric specialty pharmaceutical business with three FDA approved products and one FDA approved medical device, acquired through the acquisition of FSC Holdings, LLC (“FSC”) on February 5, 2016; and

•

Flamel is headquartered in Lyon, France and has operations in St. Louis, Missouri, United States, and Dublin, Ireland.

Basis of Presentation

Foreign Currency Translation

Reclassifications and Immaterial Corrections of Prior Period Amounts

The impact of the above errors and reclassifications on previously presented line items for each comparative period presented is as follows:



	Three Months Ended September 30, 2015
				Correction of Immaterial Errors
Consolidated Statement of Loss:	As filed			(a)			(b)			(d)			(i)		As revised

Product sales and services	$	47,320		$	—		$	—		$	(1,200	)	$	1,193	$	47,313
Total revenue	47,320			—			—			(1,200		)	1,193		47,313
Operating income (loss)	(14,479		)	—			—			(1,200		)	1,193		(14,486		)
Income (loss) before income taxes	(20,766		)	—			—			(1,200		)	1,193		(20,773		)
Income tax provision	8,919			(863		)	(751		)	(420		)	417		7,302
Net loss	(29,685		)	863			751			(780		)	776		(28,075		)
Net loss per share - basic	$	(0.73	)	$	0.02		$	0.02		$	(0.02	)	$	0.02	$	(0.69	)
Net loss per share - diluted	$	(0.73	)	$	0.02		$	0.02		$	(0.02	)	$	0.02	$	(0.69	)



	Nine Months Ended September 30, 2015
				Correction of Immaterial Errors
Consolidated Statement of Loss:	As filed			(a)			(b)			(c)			(d)			As revised

Product sales and services	$	129,841		$	—		$	—		$	(200	)	$	(1,200	)	$	128,441
Total revenue	129,841			—			—			(200		)	(1,200		)	128,441
Operating income (loss)	(5,442		)	—			—			(200		)	(1,200		)	(6,842		)
Income (loss) before income taxes	(5,804		)	—			—			(200		)	(1,200		)	(7,204		)
Income tax provision	29,634			(2,021		)	(2,607		)	(70		)	(420		)	24,516
Net loss	(35,438		)	2,021			2,607			(130		)	(780		)	(31,720		)
Net loss per share - basic	$	(0.88	)	$	0.05		$	0.06		$	—		$	(0.02	)	$	(0.79	)
Net loss per share - diluted	$	(0.88	)	$	0.05		$	0.06		$	—		$	(0.02	)	$	(0.79	)



	December 31, 2015
				Correction of Immaterial Errors									Reclassifications
Consolidated Balance Sheet:	As filed			(a)			(e)			(f)			(g)			(h)		As revised

Accounts receivable	$	6,978		$	—		$	—		$	—		$	509		$	—	$	7,487
Inventories	4,155			—			(489		)	—			—			—		3,666
Prepaid expenses and other current assets	7,989			—			—			—			—			75		8,064
Total current assets	166,306			—			(489		)	—			509			75		166,401
Other	158			—			—			—			—			9		167
Total assets	214,977			—			(489		)	—			509			84		215,081
Current portion of long-term related party payable	28,614			—			—			(3,410		)	—			—		25,204
Accounts payable	10,565			—			—			—			(5,517		)	—		5,048
Accrued expenses	3,598			—			—			—			5,710			—		9,308
Income taxes	323			(227		)	(171		)	—			—			75		—
Total current liabilities	48,788			(227		)	(171		)	(3,410		)	193			75		45,248
Long-term related party payable, less current portion	94,079			—			—			3,410			—			—		97,489
Deferred taxes	1,351			(1,360		)	—			—			—			9		—
Other	2,210			—			—			—			316			—		2,526
Total liabilities	147,112			(1,587		)	(171		)	—			509			84		145,947
Accumulated deficit	(279,793		)	1,587			(318		)	—			—			—		(278,524		)
Total shareholders' equity	67,865			1,587			(318		)	—			—			—		69,134
Total liabilities and shareholders' equity	214,977			—			(489		)	—			509			84		215,081


(a)	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).

(b)

(c)


(d)	Reflects the correction of a $1,200 understatement in the third quarter of 2015 of the gross to net revenue reserves with respect to the Company’s customer rebate calculations. As this item was originally corrected in the fourth quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.


(e)	Reflects the correction of a $489 error in the Company’s inventory obsolescence reserve accrual and expense which was originally recorded in the first quarter of 2016 but should have been recorded in the fourth quarter of 2015.


(f)	Reflects the correction of a balance sheet classification error which overstated the current portion of the long-term related party payable by $3,410.


(g)	Reflects revisions to the presentation of certain gross to net revenue reserves which were previously included in accounts payable and are now included in accrued expenses.


(h)	Reflects balance sheet reclassifications required to properly net the accrued income tax and deferred income tax amounts within the balance sheet as a result of the adjustments made in items (a) through (g) above.

(i)

Revenue

Revenue. Revenue includes sales of pharmaceutical products, amortization of licensing fees, and if any, milestone payments for R&D achievements.

Product Sales and Services

License and Research Revenue

Newly Issued Accounting Pronouncements

In August 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU”) 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows under Topic 230. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” which supersedes the most current revenue recognition requirements. This ASU requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. Through May 2016, the FASB issued ASU 2016-08 “Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU 2016-10 “Identifying Performance Obligations and Licensing,” and ASU 2016-12, “Narrow-Scope Improvements and Practical Expedients,” which provide supplemental adoption guidance and clarification to ASU 2014-09, respectively. These ASUs will be effective for annual and interim periods beginning after December 15, 2017 with early adoption for annual and interim periods beginning after December 15, 2016 permitted and should be applied retrospectively to each prior reporting period presented or as a cumulative effect adjustment as of the date of adoption. The Company is currently evaluating this pronouncement to determine the impact of its adoption on its condensed consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09 “Improvements to Employee Share-Based Payment Accounting” which amends Accounting Standards Codification (“ASC”) Topic 718 “Compensation – Stock Compensation”. This update simplifies several aspects of accounting for share-based payment awards to employees, including the accounting for income taxes, classification of awards as either equity or liabilities and classification in the statement of cash flows. The standard is effective for annual reporting periods beginning after December 15, 2016. The Company does not believe this standard will materially impact its condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02 “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. This update will be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the effect of this update on its condensed consolidated financial statements.

In September 2015, the FASB issued ASU 2015-16 “Business Combinations” which requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This ASU is effective for interim and annual reporting periods beginning after December 15, 2016, with the option to early adopt for financial statements that have not been issued. The Company early adopted the provisions of ASU 2015-16 for the year ended December 31, 2015 on a prospective basis.

In July 2015, the FASB issued ASU 2015-11 “Simplifying the Measurement of Inventory" which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The effective date for the standard is for fiscal years beginning after December 15, 2016. The new standard is to be applied prospectively and early adoption is permitted. The Company does not expect ASU 2015-11 to have a material impact on its condensed consolidated financial statements.

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Schedule of Error Corrections and Prior Period Adjustments

The impact of the above errors and reclassifications on previously presented line items for each comparative period presented is as follows:



	Three Months Ended September 30, 2015
				Correction of Immaterial Errors
Consolidated Statement of Loss:	As filed			(a)			(b)			(d)			(i)		As revised

Product sales and services	$	47,320		$	—		$	—		$	(1,200	)	$	1,193	$	47,313
Total revenue	47,320			—			—			(1,200		)	1,193		47,313
Operating income (loss)	(14,479		)	—			—			(1,200		)	1,193		(14,486		)
Income (loss) before income taxes	(20,766		)	—			—			(1,200		)	1,193		(20,773		)
Income tax provision	8,919			(863		)	(751		)	(420		)	417		7,302
Net loss	(29,685		)	863			751			(780		)	776		(28,075		)
Net loss per share - basic	$	(0.73	)	$	0.02		$	0.02		$	(0.02	)	$	0.02	$	(0.69	)
Net loss per share - diluted	$	(0.73	)	$	0.02		$	0.02		$	(0.02	)	$	0.02	$	(0.69	)



	Nine Months Ended September 30, 2015
				Correction of Immaterial Errors
Consolidated Statement of Loss:	As filed			(a)			(b)			(c)			(d)			As revised

Product sales and services	$	129,841		$	—		$	—		$	(200	)	$	(1,200	)	$	128,441
Total revenue	129,841			—			—			(200		)	(1,200		)	128,441
Operating income (loss)	(5,442		)	—			—			(200		)	(1,200		)	(6,842		)
Income (loss) before income taxes	(5,804		)	—			—			(200		)	(1,200		)	(7,204		)
Income tax provision	29,634			(2,021		)	(2,607		)	(70		)	(420		)	24,516
Net loss	(35,438		)	2,021			2,607			(130		)	(780		)	(31,720		)
Net loss per share - basic	$	(0.88	)	$	0.05		$	0.06		$	—		$	(0.02	)	$	(0.79	)
Net loss per share - diluted	$	(0.88	)	$	0.05		$	0.06		$	—		$	(0.02	)	$	(0.79	)



	December 31, 2015
				Correction of Immaterial Errors									Reclassifications
Consolidated Balance Sheet:	As filed			(a)			(e)			(f)			(g)			(h)		As revised

Accounts receivable	$	6,978		$	—		$	—		$	—		$	509		$	—	$	7,487
Inventories	4,155			—			(489		)	—			—			—		3,666
Prepaid expenses and other current assets	7,989			—			—			—			—			75		8,064
Total current assets	166,306			—			(489		)	—			509			75		166,401
Other	158			—			—			—			—			9		167
Total assets	214,977			—			(489		)	—			509			84		215,081
Current portion of long-term related party payable	28,614			—			—			(3,410		)	—			—		25,204
Accounts payable	10,565			—			—			—			(5,517		)	—		5,048
Accrued expenses	3,598			—			—			—			5,710			—		9,308
Income taxes	323			(227		)	(171		)	—			—			75		—
Total current liabilities	48,788			(227		)	(171		)	(3,410		)	193			75		45,248
Long-term related party payable, less current portion	94,079			—			—			3,410			—			—		97,489
Deferred taxes	1,351			(1,360		)	—			—			—			9		—
Other	2,210			—			—			—			316			—		2,526
Total liabilities	147,112			(1,587		)	(171		)	—			509			84		145,947
Accumulated deficit	(279,793		)	1,587			(318		)	—			—			—		(278,524		)
Total shareholders' equity	67,865			1,587			(318		)	—			—			—		69,134
Total liabilities and shareholders' equity	214,977			—			(489		)	—			509			84		215,081


(a)	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).

(b)

(c)


(d)	Reflects the correction of a $1,200 understatement in the third quarter of 2015 of the gross to net revenue reserves with respect to the Company’s customer rebate calculations. As this item was originally corrected in the fourth quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.


(e)	Reflects the correction of a $489 error in the Company’s inventory obsolescence reserve accrual and expense which was originally recorded in the first quarter of 2016 but should have been recorded in the fourth quarter of 2015.


(f)	Reflects the correction of a balance sheet classification error which overstated the current portion of the long-term related party payable by $3,410.


(g)	Reflects revisions to the presentation of certain gross to net revenue reserves which were previously included in accounts payable and are now included in accrued expenses.


(h)	Reflects balance sheet reclassifications required to properly net the accrued income tax and deferred income tax amounts within the balance sheet as a result of the adjustments made in items (a) through (g) above.

(i)

Marketable Securities (Tables)

9 Months Ended

Sep. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Available-for-sale Securities

The value at cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale marketable securities are summarized below as of:



	September 30, 2016			December 31, 2015
Marketable Securities:	September 30, 2016			December 31, 2015

Value at cost	$	131,147		$	81,395
Gross unrealized holding gains	805			15
Gross unrealized holding losses	(1,065		)	(1,672		)
Fair value	$	130,887		$	79,738

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Inventories (Tables)

9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

Schedule of Inventory

The principal categories of inventories at September 30, 2016 and December 31, 2015 are as follows:



	September 30, 2016		December 31, 2015
Inventory:	September 30, 2016		December 31, 2015

Finished goods	$	2,410	$	2,545
Raw materials	1,499		1,121
Total	$	3,909	$	3,666

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The preliminary fair values assigned to the acquired assets and liabilities have been recognized as follows:



	2016
Assigned Fair Value:	Preliminary

Accounts receivable	$	825
Inventories	2,315
Prepaid expenses and other current assets	1,712
Goodwill	643
Intangible assets:
Acquired product marketing rights	16,200
Acquired developed technology	4,400
Other assets	277
Accounts payable and other current liabilities	(4,144		)
Total	$	22,228

Business Acquisition, Pro Forma Information



	Nine Months Ended
Pro Forma Net Revenue and Losses	September 30, 2016			September 30, 2015

Net revenues	$	107,636		$	132,318
Net loss	(47,024		)	(40,724		)

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

The Company's amortizable and unamortizable intangible assets at September 30, 2016 and December 31, 2015 are as follows:



	September 30, 2016							December 31, 2015
	Gross Value		Accumulated Amortization			Net Carrying Amount		Gross Value		Accumulated Amortization			Net Carrying Amount

Amortizable intangible assets:
Acquired developed technology - Bloxiverz	$	35,248	$	(32,311	)	$	2,937	$	35,248	$	(23,498	)	$	11,750
Acquired developed technology - Vazculep	12,061		(8,597		)	3,464		12,061		(7,986		)	4,075
Acquired developed technology - Flexichamber	4,400		(293		)	4,107		—		—			—
Acquired product marketing rights	16,200		(1,200		)	15,000		—		—			—
Total amortizable intangible assets	$	67,909	$	(42,401	)	$	25,508	$	47,309	$	(31,484	)	$	15,825

Unamortizable intangible assets:
Goodwill	$	19,134	$	—		$	19,134	$	18,491	$	—		$	18,491
Total unamortizable intangible assets	$	19,134	$	—		$	19,134	$	18,491	$	—		$	18,491

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

Amortizable intangible assets are amortized over their estimated useful lives, which range from three to ten years. Estimated amortization of intangible assets for the next five years is as follows:



Years ending December 31,	Estimated Amortization Expense

2016	$	14,616
2017	3,056
2018	3,056
2019	3,056
2020	3,056
Total	$	26,840

Schedule of Goodwill

The change in net goodwill during the nine months ended September 30, 2016 is as follows:



Goodwill:

Balance, December 31, 2015	$	18,491
Impact of FSC acquisition	643
Balance, September 30, 2016	$	19,134

Long-Term Related Party Payable (Tables)

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Schedule of Related Party Transactions

Long-term related party payable and related activity are reported at fair value and consist of the following at September 30, 2016 and June 30, 2016:



				Activity during the Three Months Ended September 30, 2016
									Changes in Fair Value of Related Party Payable
	Balance, June 30, 2016			Additions		Payments to Related Parties			Operating Expense			Other Expense		Balance, September 30, 2016

Acquisition-related contingent consideration:
Warrants - Éclat Pharmaceuticals (a)	$	15,462		$	—	$	—		$	2,058		$	—	$	17,520
Earn-out payments - Éclat Pharmaceuticals (b)	114,614			—		(6,719		)	19,720			—		127,615
Royalty agreement - FSC (c)	6,505			—		(261		)	(930		)	—		5,314
Financing-related:
Royalty agreement - Deerfield (d)	9,440			—		(630		)	—			1,237		10,047
Royalty agreement - Broadfin (e)	4,500			—		(301		)	—			590		4,789
Long-term liability - FSC (f)	15,000			—		—			—			—		15,000
Total related party payable	165,521			$	—	$	(7,911	)	$	20,848		$	1,827	180,285
Less: Current portion	(29,500		)											(33,359		)
Total long-term related party payable	$	136,021												$	146,926

Long-term related party payable and related activity are reported at fair value and consist of the following at September 30, 2016 and December 31, 2015:



				Activity during the Nine Months Ended September 30, 2016
									Changes in Fair Value of Related Party Payable
	Balance, December 31, 2015			Additions		Payments to Related Parties			Operating Expense			Other Expense		Balance, September 30, 2016
Acquisition-related contingent consideration:
Warrants - Éclat Pharmaceuticals (a)	$	20,617		$	—	$	—		$	(3,097	)	$	—	$	17,520
Earn-out payments - Éclat Pharmaceuticals (b)	90,468			—		(20,934		)	58,081			—		127,615
Royalty agreement - FSC (c)	—			7,695		(386		)	(1,995		)	—		5,314
Financing-related:
Royalty agreement - Deerfield (d)	7,862			—		(1,968		)	—			4,153		10,047
Royalty agreement - Broadfin (e)	3,746			—		(939		)	—			1,982		4,789
Long-term liability - FSC (f)	—			15,000		—			—			—		15,000
Total related party payable	122,693			$	22,695	$	(24,227	)	$	52,989		$	6,135	180,285
Less: Current portion	(25,204		)											(33,359		)
Total long-term related party payable	$	97,489												$	146,926

(a)

(b)


(c)	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part included a commitment to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.


(d)	As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024.


(e)	As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.


(f)	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part consists of payments totaling $1,050 annually for five years with a final payment in January 2021 of $15,000.

Schedule Of Fair Value Assumptions Of Warrant

The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of September 30:



Assumptions for the Warrant Valuation	September 30, 2016			September 30, 2015

Stock price	$	12.40		$	16.31
Weighted average exercise price per share	8.63			8.63
Expected term (years)	1.5			2.5
Expected volatility	58.40		%	64.87		%
Risk-free interest rate	0.68		%	0.78		%
Expected dividend yield	—			—

Income Taxes (Tables)

9 Months Ended

Sep. 30, 2016

Income Tax Disclosure [Abstract]

Schedule Of Components Of Income Before Income Tax

The components of income (loss) before income taxes are as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015

United States	$	(6,814	)	$	(9,581	)	$	4,948		$	11,192
France	(6,244		)	(5,568		)	(15,333		)	3,545
Ireland	(3,485		)	(5,624		)	(17,413		)	(21,941		)
Total loss before income taxes	$	(16,543	)	$	(20,773	)	$	(27,798	)	$	(7,204	)

Schedule of Effective Income Tax Rate Reconciliation

The items accounting for the difference between the income tax provision computed at the French statutory rate and the Company's effective tax rate are as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015

Statutory tax rate	33.3		%	33.3		%	33.3		%	33.3		%
International tax rates differential	(3.6		)%	(4.8		)%	(13.3		)%	(66.0		)%
Valuation allowance on net operating losses	(2.0		)%	10.2		%	(15.3		)%	24.8		%
Nondeductible contingent consideration	(38.9		)%	(67.9		)%	(62.0		)%	(367.0		)%
Nondeductible stock-based compensation	(4.8		)%	1.7		%	(4.4		)%	54.6		%
Deferred charge from IP transfer	(1.5		)%	(2.7		)%	(2.7		)%	(8.8		)%
State and local income taxes	(1.7		)%	(1.3		)%	(2.7		)%	(7.1		)%
Other	(1.7		)%	(3.7		)%	1.6		%	(4.1		)%
Effective income tax rate	(20.9		)%	(35.2		)%	(65.5		)%	(340.3		)%

Income tax benefit - at statutory tax rate	$	(5,509	)	$	(6,917	)	$	(9,257	)	$	(2,399	)
International tax rates differential	591			1,006			3,706			4,754
Valuation allowance on net operating losses	339			(2,116		)	4,252			(1,784		)
Nondeductible contingent consideration	6,436			14,109			17,236			26,438
Nondeductible stock-based compensation	788			(357		)	1,222			(3,936		)
Deferred charge from IP transfer	246			568			739			637
State and local income taxes	280			260			757			515
Other	280			749			(443		)	291
Income tax provision - at effective income tax rate	$	3,451		$	7,302		$	18,212		$	24,516

Other Assets and Liabilities (Tables)

9 Months Ended

Sep. 30, 2016

Other Liabilities Disclosure [Abstract]

Schedule Of Prepaid Expenses and Other Current Assets

Various other assets and liabilities are summarized as follows:



	September 30, 2016		December 31, 2015
Prepaid Expenses and Other Current Assets:	September 30, 2016		December 31, 2015

Valued-added tax recoverable	$	305	$	1,099
Prepaid expenses	4,456		2,921
Advance to suppliers and other current assets	1,603		518
Income tax receivable	2,519		3,526
Total	$	8,883	$	8,064

Schedule of Other Assets, Noncurrent



	September 30, 2016		December 31, 2015
Other Non-Current Assets:	September 30, 2016		December 31, 2015

Deferred tax assets	$	6,715	$	—
Other	105		167
Total	$	6,820	$	167

Schedule of Accrued Liabilities



	September 30, 2016		December 31, 2015
Accrued Expenses:	September 30, 2016		December 31, 2015

Compensation	$	2,797	$	1,888
Social charges	1,556		1,710
Customer allowances	8,094		5,710
Other	585		—
Total	$	13,032	$	9,308

Schedule Of Other Current Liabilities



	September 30, 2016		December 31, 2015
Other Current Liabilities:	September 30, 2016		December 31, 2015

Valued-added tax payable	$	91	$	—
Other	336		133
Total	$	427	$	133

Schedule Of Long Term Liabilities



	September 30, 2016		December 31, 2015
Other Non-Current Liabilities:	September 30, 2016		December 31, 2015

Provision for retirement indemnity	$	2,324	$	2,170
Customer allowances	1,556		—
Other	427		356
Total	$	4,307	$	2,526

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation

A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
Loss Per Share	2016			2015			2016			2015

Net loss	$	(19,994	)	$	(28,075	)	$	(46,010	)	$	(31,720	)

Weighted average shares:
Basic shares	41,241			40,625			41,241			40,397
Effect of dilutive securities—options and warrants outstanding	—			—			—			—
Diluted shares	41,241			40,625			41,241			40,397

Net loss per share - basic	$	(0.48	)	$	(0.69	)	$	(1.12	)	$	(0.79	)
Net loss per share - diluted	$	(0.48	)	$	(0.69	)	$	(1.12	)	$	(0.79	)

Comprehensive Income (Loss) (Tables)

9 Months Ended

Sep. 30, 2016

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following table shows the components of accumulated other comprehensive loss for the three and nine months ended September 30, 2016 and 2015, net of tax effects:



	Three Months Ended September 30,						Nine Months Ended September 30,
Accumulated Other Comprehensive Loss	2016			2015			2016			2015

Foreign currency translation adjustment:
Beginning balance	$	(19,952	)	$	(18,612	)	$	(22,312	)	$	(7,225	)
Net other comprehensive (loss) income	1,567			102			3,927			(11,285		)
Balance at September 30	$	(18,385	)	$	(18,510	)	$	(18,385	)	$	(18,510	)

Unrealized gain (loss) on marketable securities, net
Beginning balance	$	1,102		$	(198	)	$	(345	)	$	(198	)
Net other comprehensive (loss) income, net of $152, ($9), ($49), ($9) tax, respectively	(2,405		)	(365		)	(958		)	(365		)
Balance at September 30	$	(1,303	)	$	(563	)	$	(1,303	)	$	(563	)
Accumulated other comprehensive loss at September 30	$	(19,688	)	$	(19,073	)	$	(19,688	)	$	(19,073	)

Shareholders' Equity (Tables)

9 Months Ended

Sep. 30, 2016

Stockholders' Equity Note [Abstract]

Schedule of Stockholders Equity

The following table presents a reconciliation of the Company’s beginning and ending balances in shareholders’ equity for the nine months ended September 30, 2016:



	Nine Months Ended September 30, 2016
Shareholders' Equity	Nine Months Ended September 30, 2016

Shareholders' equity - January 1	$	69,134
Net loss	(46,010		)
Other comprehensive income	2,969
Subscription of warrants	199
Stock-based compensation expense	10,541
Shareholders' equity - September 30	$	36,833

Company Operations by Product (Tables)

9 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table presents a summary of total revenues by these products:



	Three Months Ended September 30,				Nine Months Ended September 30,
Revenues	2016		2015		2016		2015

Bloxiverz	$	15,591	$	41,243	$	65,958	$	114,074
Vazculep	9,340		5,605		29,167		12,757
Akovaz	5,568		—		5,568		—
Other	841		465		4,165		1,610
Total product sales and services	31,340		47,313		104,858		128,441
License and research revenue	747		—		2,303		—
Total revenues	$	32,087	$	47,313	$	107,161	$	128,441

Summary of Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended					9 Months Ended		12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services	$ 31,340		$ 47,313			$ 104,858	$ 128,441
Total revenue	32,087		47,313			107,161	128,441
Operating income (loss)	(16,190)		(14,486)			(22,029)	(6,842)
Income (loss) before income taxes	(16,543)		(20,773)			(27,798)	(7,204)
Income tax provision	3,451		7,302			18,212	24,516
Net loss	$ (19,994)		$ (28,075)			$ (46,010)	$ (31,720)
Net loss per share - basic (in dollars per share)	$ (0.48)		$ (0.69)			$ (1.12)	$ (0.79)
Net loss per share - diluted (in dollars per share)	$ (0.48)		$ (0.69)			$ (1.12)	$ (0.79)
As filed
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services			$ 47,320				$ 129,841
Total revenue			47,320				129,841
Operating income (loss)			(14,479)				(5,442)
Income (loss) before income taxes			(20,766)				(5,804)
Income tax provision			8,919				29,634
Net loss			$ (29,685)				$ (35,438)
Net loss per share - basic (in dollars per share)			$ (0.73)				$ (0.88)
Net loss per share - diluted (in dollars per share)			$ (0.73)				$ (0.88)
Correction of Immaterial Errors \| (a)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services			$ 0				$ 0
Total revenue			0				0
Operating income (loss)			0				0
Income (loss) before income taxes			0				0
Income tax provision		$ 434	(863)	$ (292)	$ (866)		(2,021)	$ (1,587)
Net loss			$ 863				$ 2,021
Net loss per share - basic (in dollars per share)			$ 0.02				$ 0.05
Net loss per share - diluted (in dollars per share)			$ 0.02				$ 0.05
Correction of Immaterial Errors \| (b)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services			$ 0				$ 0
Total revenue			0				0
Operating income (loss)			0				0
Income (loss) before income taxes			0				0
Income tax provision		$ (2,607)	(751)	(1,026)	(830)		(2,607)		$ 693	$ (333)	$ (360)
Net loss			$ 751				$ 2,607
Net loss per share - basic (in dollars per share)			$ 0.02				$ 0.06
Net loss per share - diluted (in dollars per share)			$ 0.02				$ 0.06
Correction of Immaterial Errors \| (c)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services							$ (200)
Total revenue					$ 200		(200)
Operating income (loss)							(200)
Income (loss) before income taxes							(200)
Income tax provision							(70)
Net loss							$ (130)
Net loss per share - basic (in dollars per share)							$ 0.00
Net loss per share - diluted (in dollars per share)							$ 0.00
Correction of Immaterial Errors \| (d)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services			$ (1,200)				$ (1,200)
Total revenue			(1,200)	1,200			(1,200)
Operating income (loss)			(1,200)				(1,200)
Income (loss) before income taxes			(1,200)				(1,200)
Income tax provision			(420)				(420)
Net loss			$ (780)				$ (780)
Net loss per share - basic (in dollars per share)			$ (0.02)				$ (0.02)
Net loss per share - diluted (in dollars per share)			$ (0.02)				$ (0.02)
Correction of Immaterial Errors \| (i)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services			$ 1,193
Total revenue			1,193	$ 1,193
Operating income (loss)			1,193
Income (loss) before income taxes			1,193
Income tax provision			417
Net loss			$ 776
Net loss per share - basic (in dollars per share)			$ 0.02
Net loss per share - diluted (in dollars per share)			$ 0.02

Summary of Significant Accounting Policies (Details 1) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable	$ 15,395			$ 7,487
Inventories	3,909			3,666
Prepaid expenses and other current assets	8,883			8,064
Total current assets	177,854			166,401
Other	6,820			167
Total assets	247,985			215,081
Current portion of long-term related party payable	33,359	$ 29,500		25,204
Accounts payable	8,966			5,048
Accrued expenses	13,032			9,308
Income taxes				0
Total current liabilities	59,185			45,248
Long-term related party payable, less current portion	146,926	$ 136,021		97,489
Deferred taxes				0
Other	4,307			2,526
Total liabilities	211,152			145,947
Accumulated deficit	(324,534)			(278,524)
Total shareholders' equity	36,833			69,134
Total liabilities and shareholders' equity	$ 247,985			215,081
(g)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable				509
Inventories				0
Prepaid expenses and other current assets				0
Total current assets				509
Other				0
Total assets				509
Current portion of long-term related party payable				0
Accounts payable				(5,517)
Accrued expenses				5,710
Income taxes				0
Total current liabilities				193
Long-term related party payable, less current portion				0
Deferred taxes				0
Other				316
Total liabilities				509
Accumulated deficit				0
Total shareholders' equity				0
Total liabilities and shareholders' equity				509
(h)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable				0
Inventories				0
Prepaid expenses and other current assets				75
Total current assets				75
Other				9
Total assets				84
Current portion of long-term related party payable				0
Accounts payable				0
Accrued expenses				0
Income taxes				75
Total current liabilities				75
Long-term related party payable, less current portion				0
Deferred taxes				9
Other				0
Total liabilities				84
Accumulated deficit				0
Total shareholders' equity				0
Total liabilities and shareholders' equity				84
As filed
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable				6,978
Inventories				4,155
Prepaid expenses and other current assets				7,989
Total current assets				166,306
Other				158
Total assets				214,977
Current portion of long-term related party payable				28,614
Accounts payable				10,565
Accrued expenses				3,598
Income taxes				323
Total current liabilities				48,788
Long-term related party payable, less current portion				94,079
Deferred taxes				1,351
Other				2,210
Total liabilities				147,112
Accumulated deficit				(279,793)
Total shareholders' equity				67,865
Total liabilities and shareholders' equity				214,977
Correction of Immaterial Errors \| (a)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable				0
Inventories				0
Prepaid expenses and other current assets				0
Total current assets				0
Other				0
Total assets				0
Current portion of long-term related party payable				0
Accounts payable				0
Accrued expenses				0
Income taxes				(227)
Total current liabilities				(227)
Long-term related party payable, less current portion				0
Deferred taxes				(1,360)
Other				0
Total liabilities				(1,587)
Accumulated deficit				1,587
Total shareholders' equity				1,587
Total liabilities and shareholders' equity				0
Correction of Immaterial Errors \| (e)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable				0
Inventories			$ 489	(489)
Prepaid expenses and other current assets				0
Total current assets				(489)
Other				0
Total assets				(489)
Current portion of long-term related party payable				0
Accounts payable				0
Accrued expenses				0
Income taxes				(171)
Total current liabilities				(171)
Long-term related party payable, less current portion				0
Deferred taxes				0
Other				0
Total liabilities				(171)
Accumulated deficit				(318)
Total shareholders' equity				(318)
Total liabilities and shareholders' equity				(489)
Correction of Immaterial Errors \| (f)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable				0
Inventories				0
Prepaid expenses and other current assets				0
Total current assets				0
Other				0
Total assets				0
Current portion of long-term related party payable				(3,410)
Accounts payable				0
Accrued expenses				0
Income taxes				0
Total current liabilities				(3,410)
Long-term related party payable, less current portion				3,410
Deferred taxes				0
Other				0
Total liabilities				0
Accumulated deficit				0
Total shareholders' equity				0
Total liabilities and shareholders' equity				$ 0

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended					9 Months Ended		12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2016	Mar. 31, 2016
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Income tax benefit (expense)	$ (3,451)		$ (7,302)			$ (18,212)	$ (24,516)
Total revenues	32,087		47,313			107,161	128,441
Inventories	3,909	$ 3,666				3,909		$ 3,666
Current portion of long-term related party payable	(33,359)	(25,204)				(33,359)		(25,204)				$ (29,500)
Revenue from change in accounting estimate	$ 5,981					$ 5,981
Additional diluted net earnings (loss) (in dollars per share)	$ 0.05					$ 0.05
Correction of Immaterial Errors \| (a)
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Income tax benefit (expense)		(434)	863	$ 292	$ 866		2,021	1,587
Total revenues			0				0
Inventories		0						0
Current portion of long-term related party payable		0						0
Correction of Immaterial Errors \| (b)
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Income tax benefit (expense)		2,607	751	1,026	830		2,607		$ (693)	$ 333	$ 360
Total revenues			0				0
Correction of Immaterial Errors \| (c)
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Income tax benefit (expense)							70
Total revenues					$ 200		(200)
Correction of Immaterial Errors \| (d)
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Income tax benefit (expense)			420				420
Total revenues			(1,200)	1,200			$ (1,200)
Correction of Immaterial Errors \| (e)
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Inventories		(489)						(489)					$ 489
Current portion of long-term related party payable		0						0
Correction of Immaterial Errors \| (f)
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Inventories		0						0
Current portion of long-term related party payable		$ 3,410						$ 3,410
Correction of Immaterial Errors \| (i)
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Income tax benefit (expense)			(417)
Total revenues			$ 1,193	$ 1,193

Marketable Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Value at cost	$ 131,147	$ 81,395
Gross unrealized holding gains	805	15
Gross unrealized holding losses	(1,065)	(1,672)
Fair value	$ 130,887	$ 79,738

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Finished goods	$ 2,410	$ 2,545
Raw materials	1,499	1,121
Total	$ 3,909	$ 3,666

Acquisitions (Details Textual) - USD ($)		1 Months Ended			3 Months Ended	9 Months Ended
Acquisitions (Details Textual) - USD ($)	Feb. 05, 2016	Feb. 29, 2016	Dec. 31, 2013	Feb. 28, 2013	Sep. 30, 2016	Sep. 30, 2016
Business Combination, Separately Recognized Transactions [Line Items]
Payments to acquire businesses, gross					$ 7,911,000	$ 24,227,000
Percentage of royalty payable on net sales			0.834%
Business combination, pro forma information, loss of acquiree since acquisition date, actual					4,508,000	8,997,000
Affiliated Entity \| Deerfield CSF LLC
Business Combination, Separately Recognized Transactions [Line Items]
Percentage of royalty payable on net sales				1.75%
FSC Holdings, LLC
Business Combination, Separately Recognized Transactions [Line Items]
Business combination, consideration transferred, total	$ 22,228,000
Payment for settlement of net working capital	467,000
Business Acquisition, Transaction Costs					0	0
Business combination, pro forma information, revenue of acquiree since acquisition date, actual					$ 389,000	$ 3,026,000
FSC Holdings, LLC \| Maximum
Business Combination, Separately Recognized Transactions [Line Items]
Finite-lived intangible asset, useful life						10 years
FSC Holdings, LLC \| Minimum
Business Combination, Separately Recognized Transactions [Line Items]
Finite-lived intangible asset, useful life						7 years
FSC Holdings, LLC \| Affiliated Entity \| Deerfield CSF LLC
Business Combination, Separately Recognized Transactions [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, noncurrent liabilities, long-term debt	15,000,000
Payments to acquire businesses, gross	$ 1,050,000	$ 1,050,000
Debt instrument, term	5 years	5 years
Business combination, contingent consideration, liability, total	$ 7,695,000
Percentage of royalty payable on net sales	15.00%	15.00%
FSC Holdings, LLC \| Affiliated Entity \| Deerfield CSF LLC \| Maximum
Business Combination, Separately Recognized Transactions [Line Items]
Royalty guarantees, commitments, amount	$ 12,500,000
Royalty guarantees, commitments, term	10 years	10 years

Acquisitions (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Feb. 05, 2016	Dec. 31, 2015
Business Combination, Separately Recognized Transactions [Line Items]
Goodwill	$ 19,134		$ 18,491
FSC Holdings, LLC
Business Combination, Separately Recognized Transactions [Line Items]
Accounts receivable		$ 825
Inventories		2,315
Prepaid expenses and other current assets		1,712
Goodwill		643
Other assets		277
Accounts payable and other current liabilities		(4,144)
Total		22,228
FSC Holdings, LLC \| Product marketing rights
Business Combination, Separately Recognized Transactions [Line Items]
Intangible assets:		16,200
FSC Holdings, LLC \| Developed technology
Business Combination, Separately Recognized Transactions [Line Items]
Intangible assets:		$ 4,400

Acquisitions (Details 1) - USD ($) $ in Thousands	9 Months Ended
Acquisitions (Details 1) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015
Business Combinations [Abstract]
Net revenues	$ 107,636	$ 132,318
Net loss	$ (47,024)	$ (40,724)

Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Amortizable intangible assets:
Gross Value	$ 67,909	$ 47,309
Accumulated Amortization	(42,401)	(31,484)
Net Carrying Amount	25,508	15,825
Unamortizable intangible assets:
Gross Value	19,134	18,491
Accumulated Amortization	0	0
Net Carrying Amount	19,134	18,491
Developed technology \| Bloxiverz
Amortizable intangible assets:
Gross Value	35,248	35,248
Accumulated Amortization	(32,311)	(23,498)
Net Carrying Amount	2,937	11,750
Developed technology \| Vazculep
Amortizable intangible assets:
Gross Value	12,061	12,061
Accumulated Amortization	(8,597)	(7,986)
Net Carrying Amount	3,464	4,075
Developed technology \| Flexichamber
Amortizable intangible assets:
Gross Value	4,400	0
Accumulated Amortization	(293)	0
Net Carrying Amount	4,107	0
Product marketing rights
Amortizable intangible assets:
Gross Value	16,200	0
Accumulated Amortization	(1,200)	0
Net Carrying Amount	$ 15,000	$ 0

Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset amortization	$ 3,702	$ 3,141	$ 10,918	$ 9,423
Impairment of intangible assets					$ 7,171

Goodwill and Intangible Assets (Details 1) $ in Thousands	Sep. 30, 2016 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2016	$ 14,616
2017	3,056
2018	3,056
2019	3,056
2020	3,056
Total	$ 26,840

Goodwill and Intangible Assets (Details 2) $ in Thousands	9 Months Ended
Goodwill and Intangible Assets (Details 2) $ in Thousands	Sep. 30, 2016 USD ($)
Goodwill:
Balance, beginning	$ 18,491
Impact of FSC acquisition	643
Balance, ending	$ 19,134

Long-Term Related Party Payable (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Dec. 31, 2015
Acquisition-related contingent consideration:
Related party payable, beginning balance	$ 165,521		$ 122,693
Additions	0		22,695
Payments to Related Parties	(7,911)		(24,227)
Changes in Fair Value of Related Party Payable, Operating Expense	20,848	$ 44,782	52,989	$ 82,036
Changes in Fair Value of Related Party Payable, Other Expense	1,827		6,135
Related party payable, ending balance	180,285		180,285
Less: Current portion	(33,359)		(33,359)		$ (29,500)	$ (25,204)
Total long-term related party payable	146,926		146,926		$ 136,021	$ 97,489
Acquisition-related contingent consideration: \| Earn-out payments
Acquisition-related contingent consideration:
Related party payable, beginning balance	114,614		90,468
Additions	0		0
Payments to Related Parties	(6,719)		(20,934)
Changes in Fair Value of Related Party Payable, Operating Expense	19,720		58,081
Changes in Fair Value of Related Party Payable, Other Expense	0		0
Related party payable, ending balance	127,615		127,615
Acquisition-related contingent consideration: \| Royalty agreement - FSC
Acquisition-related contingent consideration:
Related party payable, beginning balance	6,505		0
Additions	0		7,695
Payments to Related Parties	(261)		(386)
Changes in Fair Value of Related Party Payable, Operating Expense	(930)		(1,995)
Changes in Fair Value of Related Party Payable, Other Expense	0		0
Related party payable, ending balance	5,314		5,314
Financing-related:
Acquisition-related contingent consideration:
Related party payable, beginning balance	15,000		0
Additions	0		15,000
Payments to Related Parties	0		0
Changes in Fair Value of Related Party Payable, Operating Expense	0		0
Changes in Fair Value of Related Party Payable, Other Expense	0		0
Related party payable, ending balance	15,000		15,000
Financing-related: \| Royalty agreement - Deerfield
Acquisition-related contingent consideration:
Related party payable, beginning balance	9,440		7,862
Additions	0		0
Payments to Related Parties	(630)		(1,968)
Changes in Fair Value of Related Party Payable, Operating Expense	0		0
Changes in Fair Value of Related Party Payable, Other Expense	1,237		4,153
Related party payable, ending balance	10,047		10,047
Financing-related: \| Royalty agreement - Broadfin
Acquisition-related contingent consideration:
Related party payable, beginning balance	4,500		3,746
Additions	0		0
Payments to Related Parties	(301)		(939)
Changes in Fair Value of Related Party Payable, Operating Expense	0		0
Changes in Fair Value of Related Party Payable, Other Expense	590		1,982
Related party payable, ending balance	4,789		4,789
Warrants \| Acquisition-related contingent consideration:
Acquisition-related contingent consideration:
Related party payable, beginning balance	15,462		20,617
Additions	0		0
Payments to Related Parties	0		0
Changes in Fair Value of Related Party Payable, Operating Expense	2,058		(3,097)
Changes in Fair Value of Related Party Payable, Other Expense	0		0
Related party payable, ending balance	$ 17,520		$ 17,520

Long-Term Related Party Payable (Details Textual) - USD ($)			1 Months Ended					3 Months Ended	9 Months Ended
	Feb. 05, 2016	Mar. 13, 2012	Jan. 31, 2021	Feb. 29, 2016	Dec. 31, 2013	Feb. 28, 2013	Mar. 31, 2012	Sep. 30, 2016	Sep. 30, 2016
Line of Credit Facility [Line Items]
Percentage of royalty payable on net sales					0.834%
Cash consideration received on royalty agreement					$ 2,200,000
Payments to acquire businesses, gross								$ 7,911,000	$ 24,227,000
Minimum
Line of Credit Facility [Line Items]
Discounted cash flow risk adjusted discount rate								15.00%	15.00%
Maximum
Line of Credit Facility [Line Items]
Discounted cash flow risk adjusted discount rate								32.00%	32.00%
Affiliated Entity \| Deerfield CSF LLC
Line of Credit Facility [Line Items]
Percentage of royalty payable on net sales						1.75%
Cash consideration received on royalty agreement						$ 2,600,000
Eclat Pharmaceuticals
Line of Credit Facility [Line Items]
Warrants issued (in shares)		2
Warrant term		6 years
Number of securities called by warrants (in shares)		3,300,000
Number of securities called by each warrant (in shares)		1,100,000
Exercise price of warrants (in dollars per share)		$ 11.00
Percentage of earn-out payments							20.00%
Eclat Pharmaceuticals \| Exercise Price 1
Line of Credit Facility [Line Items]
Number of securities called by each warrant (in shares)		2,200,000
Exercise price of warrants (in dollars per share)		$ 7.44
FSC Holdings, LLC \| Affiliated Entity \| Deerfield CSF LLC
Line of Credit Facility [Line Items]
Percentage of royalty payable on net sales	15.00%			15.00%
Royalty amount				$ 12,500,000
Payments to acquire businesses, gross	$ 1,050,000			$ 1,050,000
Debt instrument, term	5 years			5 years
FSC Holdings, LLC \| Affiliated Entity \| Deerfield CSF LLC \| Scenario, Forecast
Line of Credit Facility [Line Items]
Final payments to acquire business gross			$ 15,000,000
FSC Holdings, LLC \| Affiliated Entity \| Deerfield CSF LLC \| Maximum
Line of Credit Facility [Line Items]
Royalty guarantees, commitments, term	10 years			10 years

Long-Term Related Party Payable (Details 1) - Warrants - $ / shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Schedule of Capitalization, Long-term Debt [Line Items]
Stock price (in dollars per share)	$ 12.40	$ 16.31
Weighted average exercise price per share (in dollars per share)	$ 8.63	$ 8.63
Expected term	1 year 6 months	2 years 6 months
Expected volatility	58.40%	64.87%
Risk-free interest rate	0.68%	0.78%
Expected dividend yield	0.00%	0.00%

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Taxes [Line Items]
Income (loss) before income taxes	$ (16,543)	$ (20,773)	$ (27,798)	$ (7,204)
United States
Income Taxes [Line Items]
Income (loss) before income taxes	(6,814)	(9,581)	4,948	11,192
France
Income Taxes [Line Items]
Income (loss) before income taxes	(6,244)	(5,568)	(15,333)	3,545
Ireland
Income Taxes [Line Items]
Income (loss) before income taxes	$ (3,485)	$ (5,624)	$ (17,413)	$ (21,941)

Income Taxes (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Income Taxes (Details 1) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Statutory tax rate	33.30%	33.30%	33.30%	33.30%
International tax rates differential	(3.60%)	(4.80%)	(13.30%)	(66.00%)
Valuation allowance on net operating losses	(2.00%)	10.20%	(15.30%)	24.80%
Nondeductible contingent consideration	(38.90%)	(67.90%)	(62.00%)	(367.00%)
Nondeductible stock-based compensation	(4.80%)	1.70%	(4.40%)	54.60%
Deferred charge from IP transfer	(1.50%)	(2.70%)	(2.70%)	(8.80%)
State and local income taxes	(1.70%)	(1.30%)	(2.70%)	(7.10%)
Other	(1.70%)	(3.70%)	1.60%	(4.10%)
Effective income tax rate	(20.90%)	(35.20%)	(65.50%)	(340.30%)
Income tax benefit - at statutory tax rate	$ (5,509)	$ (6,917)	$ (9,257)	$ (2,399)
International tax rates differential	591	1,006	3,706	4,754
Valuation allowance on net operating losses	339	(2,116)	4,252	(1,784)
Nondeductible contingent consideration	6,436	14,109	17,236	26,438
Nondeductible stock-based compensation	788	(357)	1,222	(3,936)
Deferred charge from IP transfer	246	568	739	637
State and local income taxes	280	260	757	515
Other	280	749	(443)	291
Income tax provision - at effective income tax rate	$ 3,451	$ 7,302	18,212	24,516
Increase (decrease) in deferred tax valuation allowance			$ 3,343	$ (3,360)

Other Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Prepaid Expenses and Other Current Assets:
Valued-added tax recoverable	$ 305	$ 1,099
Prepaid expenses	4,456	2,921
Advance to suppliers and other current assets	1,603	518
Income tax receivable	2,519	3,526
Total	$ 8,883	$ 8,064

Other Assets and Liabilities (Details 1) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Other Non-Current Assets:
Deferred tax assets	$ 6,715	$ 0
Other	105	167
Total	$ 6,820	$ 167

Other Assets and Liabilities (Details 2) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accrued Expenses:
Compensation	$ 2,797	$ 1,888
Social charges	1,556	1,710
Customer allowances	8,094	5,710
Other	585	0
Total	$ 13,032	$ 9,308

Other Assets and Liabilities (Details 3) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Other Current Liabilities:
Valued-added tax payable	$ 91	$ 0
Other	336	133
Total	$ 427	$ 133

Other Assets and Liabilities (Details 4) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Other Non-Current Liabilities:
Provision for retirement indemnity	$ 2,324	$ 2,170
Customer allowances	1,556	0
Other	427	356
Total	$ 4,307	$ 2,526

Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Net loss	$ (19,994)	$ (28,075)	$ (46,010)	$ (31,720)
Weighted average shares:
Basic shares (in shares)	41,241	40,625	41,241	40,397
Effect of dilutive securities—options and warrants outstanding (in shares)	0	0	0	0
Diluted shares (in shares)	41,241	40,625	41,241	40,397
Net loss per share - basic (in dollars per share)	$ (0.48)	$ (0.69)	$ (1.12)	$ (0.79)
Net loss per share - diluted (in dollars per share)	$ (0.48)	$ (0.69)	$ (1.12)	$ (0.79)

Net Loss Per Share (Details Textual) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	6,860	6,860	6,088	6,088

Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Accumulated Other Comprehensive Loss
Beginning balance			$ 69,134
Net other comprehensive (loss) income	$ (20,832)	$ (28,338)	(43,041)	$ (43,370)
Ending balance	36,833		36,833
Foreign currency translation adjustment:
Accumulated Other Comprehensive Loss
Beginning balance	(19,952)	(18,612)	(22,312)	(7,225)
Net other comprehensive (loss) income	1,567	102	3,927	(11,285)
Ending balance	(18,385)	(18,510)	(18,385)	(18,510)
Unrealized gain (loss) on marketable securities, net
Accumulated Other Comprehensive Loss
Beginning balance	1,102	(198)	(345)	(198)
Net other comprehensive (loss) income	(2,405)	(365)	(958)	(365)
Ending balance	(1,303)	(563)	(1,303)	(563)
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Loss
Ending balance	$ (19,688)	$ (19,073)	$ (19,688)	$ (19,073)

Comprehensive Income (Loss) (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Unrealized gain (loss) on marketable securities, tax	$ 152	$ (9)	$ (49)	$ (9)

Shareholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Shareholders' Equity (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Shareholders' Equity
Beginning balance			$ 69,134
Net loss	$ (19,994)	$ (28,075)	(46,010)	$ (31,720)
Other comprehensive income	(838)	$ (263)	2,969	$ (11,650)
Subscription of warrants			199
Stock-based compensation expense			10,541
Ending balance	$ 36,833		$ 36,833

Company Operations by Product (Details) $ in Thousands	3 Months Ended		9 Months Ended
Company Operations by Product (Details) $ in Thousands	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) segment	Sep. 30, 2015 USD ($)
Company Operations by Product [Line Items]
Number of operating segments (in segments) \| segment			1
Total product sales and services	$ 31,340	$ 47,313	$ 104,858	$ 128,441
License and research revenue	747	0	2,303	0
Total	32,087	47,313	107,161	128,441
Bloxiverz
Company Operations by Product [Line Items]
Total product sales and services	15,591	41,243	65,958	114,074
Vazculep
Company Operations by Product [Line Items]
Total product sales and services	9,340	5,605	29,167	12,757
Akovaz
Company Operations by Product [Line Items]
Total product sales and services	5,568	0	5,568	0
Other
Company Operations by Product [Line Items]
Total product sales and services	$ 841	$ 465	$ 4,165	$ 1,610